Michael Cutter

I joined Biocon Biologics at a time when global healthcare is at an inflection point for biosimilars and as Biocon acquires the biosimilar business of Viatris. Leading the transformation of the Quality organisation on our journey to bring access to healthcare through affordable biologics at a transformative time for healthcare, I bring 30 years of experience to a driven and passionate organisation. 

Having made multiple transformations in performance, network and digital health at Merck, I step into a new role with only thanks and deep admiration for the leadership team at Merck. We did such amazing things together even through covid and it was a complete blessing to work with each of them. I wish the Merck team every success as I start such an exciting next chapter with Biocon.

Before joining Merck, I transformed the quality culture at Novartis following the 2011 global Warning Letter and was the lead in preparation for and and hosting health authority inspections for launch molecules including Entresto and Cosentyx.

I am a biochemist by qualification, driver of sustainability and connector of people. To achieve these things, I have become a passionate storyteller such that people are able to do things they never imagined!